论文部分内容阅读
目的:观察脑心通胶囊联合辛伐他汀治疗混合型高脂血症的疗效及安全性。方法:将符合诊断的108例混合型高脂血症患者,随机分为2组。治疗组54例,服用脑心通胶囊,每次3粒,每天3次口服;辛伐他汀20mg,每天1次睡前口服。对照组54例,单给予辛伐他汀20mg,每天1次睡前口服。分别于治疗12周后观察血脂的变化。结果:临床控制率治疗组33.33%,对照组12.96%;总有效率治疗组94.44%,对照组72.22%。2组临床控制率、总有效率比较,差异均有非常显著性意义(P<0.01)。治疗后,2组患者血清TC、TG、LDL-C、HDL-C水平均有不同程度改善,与治疗前比较,差异有显著性或非常显著性意义(P<0.05,P<0.01)。治疗组TG、LDL-C降低幅度和HDL-C升高幅度明显优于对照组,与对照组比较,差异有显著性或非常显著性意义(P<0.05,P<0.01)。结论:脑心通胶囊联合辛伐他汀可以更好地改善混合型高脂血症患者的血脂异常,具有良好的安全性和耐受性。
Objective: To observe the efficacy and safety of Naoxintong capsule combined with simvastatin in the treatment of mixed hyperlipidemia. Methods: One hundred and eighty patients with hyperlipidemia were randomly divided into two groups. Treatment group of 54 cases, taking Naoxintong capsules, 3 capsules three times a day orally; simvastatin 20mg, 1 times a day before going to bed orally. Control group of 54 patients, given a single simvastatin 20mg, 1 times a day before going to bed orally. Blood lipids were observed after 12 weeks of treatment. Results: The clinical control rate was 33.33% in the treatment group and 12.96% in the control group. The total effective rate was 94.44% in the treatment group and 72.22% in the control group. The two groups of clinical control rate, total effective rate comparison, the difference was very significant (P <0.01). After treatment, the levels of serum TC, TG, LDL-C and HDL-C in both groups were improved to some extent. There was a significant difference between the two groups (P <0.05, P <0.01). The reduction of TG and LDL-C and the increase of HDL-C in the treatment group were significantly better than those in the control group, and the difference was significant or very significant (P <0.05, P <0.01). Conclusion: Naoxintong capsule combined with simvastatin can better improve the dyslipidemia in patients with mixed hyperlipidemia, with good safety and tolerability.